JSJunichiro Sageshima

Junichiro Sageshima

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Junichiro Sageshima has a total of 137 co-authors. Here are the top co-authors by number of shared publications:

  • Gaetano Ciancio

    Department of Surgery, University of Miami Miller School of Medicine and Miami Transplant Institute, Miami, FL, USA

    7 shared publications
  • Linda Chen

    Department of Surgery, University of Miami Miller School of Medicine and Miami Transplant Institute, Miami, FL, USA

    7 shared publications
  • George W. Burke

    Department of Surgery, University of Miami Miller School of Medicine and Miami Transplant Institute, Miami, FL, USA

    5 shared publications
  • Phillip Ruiz

    The Lillian Jean Kaplan Renal Transplant Center and the Miami Transplant Institute, Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA

    5 shared publications
  • Gaetano Ciancio

    Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA

    4 shared publications
  • George William Burke

    Department of Medicine. Peggy and Harold Katz Family drug Discovery Center and Division of nephrology and Hypertension. University of Miami and Miami Transplant Institute, Miami, FL

    4 shared publications

Latest Publications

  • Open Access

    Prolonged wait times among highly sensitized HLA-B46 homozygous kidney transplant candidates

    by Carrie L. Butler, Loren Gragert, Anh Du, Yuxin Yin, Mario A. Pulido, Nezar Eltayeb Elsheikh, Sun-Mi Choi, Michelle J. Hickey, Qiuheng J. Zhang, Olga Timofeeva, et al.

  • Baseline Vascular Pathology in Deceased Donor Kidneys: Differential Impact on Transplant Outcomes by Donor Type

    by Junichiro Sageshima, Naeem Goussous, Yvonne Kelly, Caitlin Loseth, Karima Alghannam, Ling‐Xin Chen, Lea Matsuoka, Sophoclis Alexopoulos, Richard Perez, Kuang‐Yu Jen

    Background: The impact of kidney vascular pathology on transplant outcomes remains poorly understood, particularly under specific donor conditions. Methods: This retrospective single‐center study analyzed 837 deceased donor kidney transplants. Based on baseline vascular histology, the kidneys were categorized into two groups: minimal vascular disease (Group 0, n = 637) and significant vascular disease (Group 1, n = 200). Five‐year graft survival and 6‐ and 12‐month kidney function were evaluated, along with subgroup analyses of various donor characteristics. Propensity score matching was used to adjust for confounding factors. Results: Recipients of kidneys with significant vascular disease showed worse 5‐year overall graft survival (64.6% vs. 80.0%, p = 0.0002) and death‐censored graft survival (85.6% vs. 91.5%, p = 0.0126). These differences persisted after propensity score matching. The impact was most pronounced in hypertensive donors (53.4% vs. 84.9%) and diabetic donors (52.3% vs. 69.0%). Circulatory death donors showed immediate adverse effects, while brain death donors demonstrated delayed deterioration. Kidneys with significant vascular disease exhibited lower glomerular filtration rates at follow‐up. Conclusion: Baseline vascular disease in deceased donor kidneys has a significant impact on transplant outcomes, independent of clinical risk factors. These findings support the incorporation of vascular histological assessment into donor evaluation to enhance risk stratification and optimize post‐transplant management.


  • Open Access

    Packed Red Blood Cell and Whole Blood Perfusates during Ex Vivo Normothermic Perfusion for Assessment of High-Risk Donor Kidneys

    by Armin Ahmadi, Heiko Yang, Kuang-Yu Jen, Sili Fan, Ivonne Palma, Junichiro Sageshima, Naeem Goussous, Baback Roshanravan, Richard V. Perez

    Key Points: Compared with whole blood (WB) kidneys perfused with a packed red blood cells perfusate exhibited superior kidney functional parameters. Metabolomics assessment showed drastic metabolic aberration in the WB group involving amino acid, carbohydrate, and mitochondrial energy metabolism. Tissue lipid profiling demonstrated that WB was associated with accumulation of tissue membrane/structure components including glycerolipids and ceramides. Background: Ex vivo normothermic perfusion (EVNP) with a blood-based perfusate has the potential to both assess viability of and repair high-risk organs before transplantation. The optimal perfusate is yet to be established. Methods: We assessed hemodynamic, functional, and metabolic changes of eight paired high-risk human kidneys perfused with either a leukocyte-depleted packed red blood cell (PRBC) or a whole blood (WB) perfusate during a 3-hour EVNP. Results: After a mean cold ischemia time of 54 hours, all kidneys showed high renal blood flow through perfusion. Renal resistance increased for both groups during the first hour and then decreased to similar terminal values. The kidneys perfused with PRBC had 55 ml/min greater renal blood flow (95% confidence interval, 21 to 89; P = 0.004) and higher total urine output (145 versus 25 ml, P = 0.002) compared with the WB group. Urinary acute kidney biomarkers of neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 were also significantly lower (mean differences of 281 and 2.1 ng/ml, respectively; P < 0.01) in the PRBC perfused kidneys. Compared with PRBC, within-group tissue metabolic profiling revealed a similar (23% versus 18%) but a more pronounced alteration involving (branched chain) amino acid and mitochondrial energy metabolism in the WB group. Similarly, lipid profile temporal changes showed that WB groups were highlighted by elevation of plasma membrane and structure lipids including glycerolipids, sphingolipids, and steroids. The PRBC group had minimal temporal tissue lipid profile changes. Conclusions: Compared with WB, PRBC perfusion is superior in mitigating postischemia damage and facilitating function and metabolic recovery of high-risk kidneys subjected to long cold ischemia times during a 3-hour EVNP.

  • Open Access

    Outcomes of Kidney Transplantation From Donors on Renal Replacement Therapy

    by Naeem Goussous, Karima Bs Alghannam, Peter A. Than, Aileen X. Wang, Ling-Xin Chen, Sophoclis P. Alexopoulos, Junichiro Sageshima, Richard V. Perez

    Background.: The increasing demand for organs has pushed transplant providers to expand kidney acceptance criteria. The use of kidneys from donors with AKI has been shown to provide good long-term graft survival. We aim to evaluate and compare the outcomes of deceased donor kidney transplantation from donors with acute kidney injury (AKI), either with or without renal replacement therapy (AKI-RRT) before donation. Methods.: A single-center retrospective review of all patients who underwent deceased donor kidney transplantation from AKI donors between 2009 and 2020 was performed. AKI donors were defined on the basis of donor terminal creatinine ≥2.0 mg/dL or use of RRT before donation. We compared the outcomes of recipients receiving a kidney from a donor with AKI versus AKI-RRT. Data are presented as medians (interquartile ranges) and numbers (percentages). Results.: Four hundred ninety-six patients were identified, of whom 300 (60.4%) were men with a median age of 57 y at transplantation. Thirty-nine patients received an AKI-RRT, whereas 457 received an AKI kidney. Donors in the AKI-RRT group were younger (28 versus 40), had less incidence of hypertension (15.3% versus 31.9%), and were more likely to be imported (94.9% versus 76.8%). There was a higher incidence of delayed graft function (72% versus 44%, P < 0.001) in the AKI-RRT group. Recipients in both groups had similar 90-d (100% versus 95.2%) and 1-y (100% versus 91.9%) graft survival. With a median follow-up of 5 y, there was no difference in death-censored graft survival in both groups (P = 0.83). Conclusions.: Careful selection of kidneys from donors with AKI on RRT can be safely used for kidney transplantation with favorable clinical outcomes.


  • Open Access

    Impact of Warm Ischemia Time on Donation After Circulatory Death Kidney Transplant Outcomes

    by Karima Alghannam, Jeffrey Fine, Brian Howard, Jennifer Loza, Naeem M. Goussous, Junichiro Sageshima, Neal M. Mineyev, Aileen X. Wang, Richard V. Perez, Peter A. Than

    Background: Efforts to address the shortage of donor organs include increasing the use of renal allografts from donors after circulatory death (DCD). While warm ischemia time (WIT) is thought to be an important factor in DCD kidney evaluation, few studies have compared the relationship between WIT and DCD kidney outcomes, and WIT acceptance practices remain variable.Methods: We conducted a single‐center retrospective review of all adult patients who underwent deceased donor kidney transplantation from 2000 to 2021. We evaluated the impact of varied functional warm ischemia time (fWIT) in controlled DCD donors by comparing donor and recipient characteristics and posttransplant outcomes between high fWIT (>60 min), low fWIT (≤60 min), and kidneys transplanted from donors after brain death (DBD).Results: Two thousand eight hundred eleven patients were identified, 638 received low fWIT DCD, 93 received high fWIT DCD, and 2080 received DBD kidneys. There was no significant difference in 5‐year graft survival between the DCD low fWIT, high fWIT, and DBD groups, with 84%, 83%, and 83% of grafts functioning, respectively. Five‐year patient survival was 91% in the low fWIT group, 92% in the high fWIT group, and 90% in the DBD group. An increase in kidney donor risk index (KDRI) (HR 3.37, 95% CI = 2.1–5.7) and high CIT compared to low CIT (HR 2.12, 95% CI = 1.4–3.1) have higher hazard ratios for 1‐year graft failure.Conclusions: Increased acceptance of kidneys from selected DCD donors with prolonged fWIT may present an opportunity to increase kidney utilization while preserving outcomes. Our group specifically prioritizes the use of kidneys from younger donors, with lower KDPI, and without acute kidney injury, or risk factors for underlying chronic kidney disease.


  • Concerns Over Prediction of Kidney Discard and Nonrecovery—Reply

    by Junichiro Sageshima

    In Reply I appreciate the inquiry from Zheng et al regarding our recent article describing the feasibility of machine learning (ML) and natural language

  • Open Access

    Effectiveness of Postoperative Single-shot and Continuous Transverse Abdominis Plane Block Compared to Conventional Analgesia in Hand-assisted Laparoscopic Live-donor Nephrectomy

    by Fransia Ba De Leon, Karima Bs Alghannam, Hadia Lala Bs Gul, Naeem Goussous, Neal Mineyev, Peter A. Than, Richard V. Perez, Junichiro Sageshima

    Background.: Few studies have evaluated the efficacy of transverse abdominis plane (TAP) block in patients undergoing hand-assisted laparoscopic live-donor nephrectomy (HALN). We aimed to evaluate the analgesic effectiveness of TAP block as part of a multimodal pain management regimen in patients undergoing HALN. Methods.: We retrospectively reviewed the medical records of living kidney donors at our center between June 2016 and February 2020. HALNs were performed via a transperitoneal approach through a suprapubic incision. Additional laparoscopic ports were used in the upper midabdomen. In consenting donors, TAP block was performed postoperatively under ultrasound guidance with either a single-shot or continuous infusion of long-acting local anesthetic (0.2%–0.5% ropivacaine). All the patients received postoperative around-the-clock ketorolac and acetaminophen. Results.: Overall, 72 donors received the block (block group, 38 single-shot, 34 continuous), whereas 86 donors did not receive the block (control group). Baseline characteristics were comparable between the groups except for body weight (control: 71.8 ± 13.3 versus block: 77.8 ± 17.3 kg; P = 0.01) and intraoperative opioid dose (32.1 ± 9.6 versus 26.6 ± 10.7 morphine milligram equivalents; P < 0.001). After adjusting for baseline differences, postoperative opioid requirements were similar between the groups. When the baseline pain scale was adjusted for, there was no difference in the overall pain scale scores between the groups (P = 0.242). Subgroup analyses comparing single-shot or continuous TAP versus control did not show any differences. Conclusions.: With the caveat of the retrospective nature of the study, the adjunctive effect of TAP block after transabdominal HALN was limited when other multimodal analgesia was used.


  • Open Access

    A bio-instructive parylene-based conformal coating suppresses thrombosis and intimal hyperplasia of implantable vascular devices

    by Dake Hao, Jonathan Lin, Ruiwu Liu, Christopher Pivetti, Kaeli Yamashiro, Linda M. Schutzman, Junichiro Sageshima, Mimmie Kwong, Nataliya Bahatyrevich, Diana L. Farmer, et al.

    Implantable vascular devices are widely used in clinical treatments for various vascular diseases. However, current approved clinical implantable vascular devices generally have high failure rates primarily due to their surface lacking inherent functional endothelium. Here, inspired by the pathological mechanisms of vascular device failure and physiological functions of native endothelium, we developed a new generation of bioactive parylene (poly(p-xylylene))-based conformal coating to address these challenges of the vascular devices. This coating used a polyethylene glycol (PEG) linker to introduce an endothelial progenitor cell (EPC) specific binding ligand LXW7 (cGRGDdvc) onto the vascular devices for preventing platelet adhesion and selectively capturing endogenous EPCs. Also, we confirmed the long-term stability and function of this coating in human serum. Using two vascular disease-related large animal models, a porcine carotid artery interposition model and a porcine carotid artery-jugular vein arteriovenous graft model, we demonstrated that this coating enabled rapid generation of self-renewable “living” endothelium on the blood contacting surface of the expanded polytetrafluoroethylene (ePTFE) grafts after implantation. We expect this easy-to-apply conformal coating will present a promising avenue to engineer surface properties of “off-the-shelf” implantable vascular devices for long-lasting performance in the clinical settings.


  • Recurrence of Type 1 Diabetes Mellitus

    by George W. Burke, Gaetano Ciancio, Mahmoud Morsi, Jose Figueiro, Linda Chen, Junichiro Sageshima, Francesco Vendrame, Alberto Pugliese

  • Open Access

    Urologic complications after transplantation of 225 en bloc kidneys from small pediatric donors ≤20 kg: Incidence, management, and impact on graft survival

    by Ghaneh Fananapazir, Gary Tse, Ryan Di Geronimo, John McVicar, Richard Perez, Chandrasekar Santhanakrishnan, Junichiro Sageshima, Christoph Troppmann